黑色素瘤幸存者第二原发皮肤及非皮肤黑色素瘤的生存影响
该研究基于SEER-17数据库2004–2020年数据,纳入7314例第二原发皮肤黑色素瘤(SPCM)和157例第二原发非皮肤黑色素瘤(SPNCM)幸存者,采用灵活参数模型评估其相对于单发黑色素瘤的总生存影响。结果显示,区域/远处期SPCM和SPNCM与更差的总生存相关,提示需加强第二原发肿瘤的预防和早期检测。
要点
- 黑色素瘤幸存者中SPCM发生率为3.4%,其中12.9%为区域/远处期。
- 区域/远处期SPCM较单发CM总生存更差(HR=1.71,95%CI 1.55–1.89)。
- 非皮肤黑色素瘤幸存者中区域/远处期SPCM生存影响更显著(HR=2.67)。
核心结论
- 黑色素瘤幸存者发生SPCM和SPNCM与总生存降低相关,提示需对第二原发肿瘤进行预防和早期检测。
研究设计与样本
- 基于SEER-17 Research Plus数据库2004–2020年数据的回顾性队列研究,纳入全年龄皮肤及非皮肤黑色素瘤幸存者,识别SPCM 7314例和SPNCM 157例,采用灵活参数模型评估时变效应。
主要发现
- 研究期间3.4%患者发生SPCM(其中12.9%为区域/远处期),0.1%发生SPNCM(其中36.3%为区域/远处或未知期)。
- 与单发皮肤黑色素瘤相比,区域/远处期SPCM(HR=1.71,95%CI 1.55–1.89)和局部期SPCM(HR=1.09,95%CI 1.01–1.18)总生存更差。
- 与单发皮肤黑色素瘤相比,区域/远处期SPNCM第1年HR=1.56(95%CI 0.81–3.03)。
- 非皮肤黑色素瘤幸存者中,区域/远处期SPCM(HR=2.67,95%CI 1.73–4.13)较局部期SPCM(HR=1.19,95%CI 0.71–1.99)对总生存降低影响更明显。
- 非皮肤黑色素瘤幸存者中,区域/远处期SPNCM第2年HR=1.39(95%CI 0.76–2.54),局部期SPNCM第2年HR=0.96(95%CI 0.61–1.50)。
临床怎么用
- 对黑色素瘤幸存者应关注第二原发皮肤及非皮肤黑色素瘤的发生,尤其区域/远处期病变对生存影响显著。
- 临床随访中可考虑加强第二原发肿瘤的预防宣教和早期检测策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Melanoma survivors have a high risk of developing second primary neoplasms, both cutaneous melanoma (SPCM) and non-cutaneous melanoma (SPNCM), but little is known about the survival impact of the diagnosis of SPCM and SPNCM. OBJECTIVES: To compare overall survival between melanoma survivors with first primary melanoma and SPCM/SPNCM by stage at diagnosis of second primary neoplasms. METHODS: Among cutaneous (CM) and non-cutaneous melanoma (NCM) survivors of all ages, SPCM (N = 7314) or SPNCM (N = 157) between 2004 and 2020 were identified from the Surveillance, Epidemiology, and End Results 17 Research Plus database. Flexible parametric modelling was conducted to evaluate the time-varying effect of SPCM and SPNCM, compared to single melanoma, on survival. RESULTS: Over the study period, 3.4% of patients had a SPCM (12.9% regional/distant-stage) and 0.1% had a SPNCM (36.3% regional/distant or unknown-stage). Compared with single CM, patients with SPCM (regional/distant-stage hazard ratio [HR] = 1.71, 95% confidence interval [CI] = 1.55-1.89; localized-stage HR = 1.09, CI = 1.01-1.18) and regional/distant-stage SPNCM (Year 1: HR = 1.56, CI = 0.81-3.03) had worse overall survival. Among NCM survivors, regional/distant-stage SPCM (HR = 2.67, CI = 1.73-4.13) had a more pronounced impact on decreased overall survival than localized-stage SPCM (HR = 1.19, CI = 0.71-1.99) when compared with single NCM, with similar trends seen for regional/distant-stage SPNCM (Year 2: HR = 1.39, CI = 0.76-2.54) relative to localized-stage SPNCM (Year 2: HR = 0.96, CI = 0.61-1.50). CONCLUSIONS: The reduction in survival among melanoma survivors with SPCM and SPNCM suggests the potential need for prevention and early detection of SPCM and SPNCM.
引用
- Xie J, Kiuru M, Pollock BH, et al. Survival impact of second primary cutaneous and non-cutaneous melanoma in melanoma survivors. J Eur Acad Dermatol Venereol. 2025. PMID: 40990149. doi:10.1111/jdv.70043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。